325.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$313.13
Aprire:
$316.51
Volume 24 ore:
1.00M
Relative Volume:
0.99
Capitalizzazione di mercato:
$39.44B
Reddito:
$2.35B
Utile/perdita netta:
$-269.70M
Rapporto P/E:
-155.50
EPS:
-2.09
Flusso di cassa netto:
$-75.39M
1 W Prestazione:
+5.28%
1M Prestazione:
+12.08%
6M Prestazione:
+33.61%
1 anno Prestazione:
+45.81%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-31 | Iniziato | Redburn Atlantic | Buy |
2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
2024-02-16 | Downgrade | Goldman | Buy → Neutral |
2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
2023-09-29 | Iniziato | Raymond James | Outperform |
2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2023-04-26 | Iniziato | SMBC Nikko | Neutral |
2023-03-21 | Iniziato | Bernstein | Outperform |
2023-01-18 | Iniziato | Canaccord Genuity | Buy |
2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
2022-06-07 | Iniziato | William Blair | Outperform |
2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-03-01 | Iniziato | Citigroup | Buy |
2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
2021-02-12 | Reiterato | H.C. Wainwright | Buy |
2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2020-09-30 | Ripresa | Berenberg | Hold |
2020-09-08 | Iniziato | Citigroup | Buy |
2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
2020-04-24 | Ripresa | Evercore ISI | Outperform |
2020-03-19 | Iniziato | Berenberg | Buy |
2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
2019-11-20 | Iniziato | Oppenheimer | Outperform |
2019-11-13 | Iniziato | BofA/Merrill | Buy |
2019-05-23 | Ripresa | Goldman | Neutral |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2019-01-23 | Iniziato | UBS | Neutral |
2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
2018-08-13 | Reiterato | Stifel | Buy |
2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
2018-05-04 | Reiterato | Stifel | Hold |
2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharma Appoints New Chief R&D Officer - TipRanks
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener
Alnylam Promotes Pushkal Garg to Chief Research and Development Officer - citybiz
Alnylam appoints Pushkal Garg as chief research and development officer - Investing.com Australia
Alnylam appoints Pushkal Garg as chief research and development officer By Investing.com - Investing.com Nigeria
Alnylam (ALNY) Names New Chief R&D Officer to Drive Innovation | - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
Alnylam Pharmaceuticals stock hits all-time high at $311.24 By Investing.com - Investing.com Canada
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Japan’s Isshiki bolsters life sciences practice with senior hire - | Asian Legal Business
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada
Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Where are the Opportunities in (ALNY) - news.stocktradersdaily.com
Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey
John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada
Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com
Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN
Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus
European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus
Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - MarketScreener
EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus
(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Option Exercise |
118.73 |
19,297 |
2,291,057 |
68,245 |
Greenstreet Yvonne | Chief Executive Officer |
May 30 '25 |
Sale |
304.39 |
31,640 |
9,630,902 |
48,948 |
Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Sale |
306.00 |
19,297 |
5,904,882 |
48,948 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):